Universal Health Services (UHS) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive but not without risk — the single biggest swing factor is the size of the Florida Medicaid supplemental payment (FY2025 program, ~$100M incremental benefit expected in Q2), which alone could drive a meaningful beat if recorded as guided, while the steepening exchange subsidy headwind and Palm Beach Gardens startup drag are the primary offsets.

Heading into Q2 2026, the bar for UHS is moderately elevated but achievable: consensus sits at $5.96 diluted operating EPS and ~$4.59B in revenue, both implying solid year-over-year growth off a strong Q2 2025 base. Management reiterated full-year guidance on the Q1 call and at both the BofA (May 12) and Goldman Sachs (June 9) healthcare conferences, projecting a back-half-weighted earnings ramp to achieve 5% core growth — a posture that is confident but explicitly dependent on Cedar Hill improvement, new acute capacity ramping in Las Vegas, West Coast Florida, and Riverside County, and continued behavioral volume recovery toward the 2%–3% target. Estimate revisions have been modestly positive since the Q1 print, with the FY2026 operating EPS consensus ticking up from $23.46 to $23.52, suggesting the Street is incrementally constructive but not aggressively chasing the stock. The stock has underperformed sharply since Q1 earnings — down ~4% vs. IHF +18.5% and SPY +3.8% — reflecting investor concern about exchange subsidy headwinds, Medicaid policy risk, and the Talkspace acquisition overhang, leaving the multiple compressed and the setup asymmetric to the upside if Q2 execution is clean. The key wildcard is the Florida FY2025 Medicaid supplemental payment: management guided to ~$100M incremental benefit to be recorded in Q2, but the exact timing and sizing remain subject to state approval mechanics — any upside surprise here (as occurred with Nevada/Ohio in Q1) could drive a meaningful beat, while any delay would be a headwind.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar — the Florida Medicaid supplemental payment (~$100M) is the biggest swing factor for the quarter, while behavioral same-store adjusted patient day growth (consensus ~1.66% vs. management’s 2%–3% target) is the key operational KPI to watch for evidence of the volume recovery thesis.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data (Net revenues, Diluted EPS – operating, EBITDA – operating, Revenue – Acute care – SS%, Revenue – Behavioral Health – SS%, Adjusted Admissions – Acute care – SS%, Adjusted patient days – Behavioral health – SS%, Net rev. per adj. admission – Acute care, Net rev. per adj. admission – Behavioral Health); UHS Q1 2026 Earnings Call (April 28, 2026); BofA Healthcare Conference (May 12, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Diluted Operating EPS & Behavioral SS Adj. Patient Day Growth)

Pattern: UHS has beaten on operating EPS in 7 of the last 8 quarters — a remarkably consistent track record — while behavioral same-store adjusted patient day growth has missed or come in at the low end of consensus in 6 of 8 quarters, underscoring that volume execution in behavioral health remains the persistent soft spot even as EPS beats are driven by pricing, supplemental payments, and expense discipline.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management’s tone has been consistent and confident since the Q1 print — full-year guidance was reiterated at both the BofA and Goldman Sachs conferences — but the Florida FY2025 Medicaid supplemental payment (~$100M incremental benefit) is the one material item that has been formally disclosed post-Q1 and will be recorded in Q2, representing the most significant guidance-adjacent development since last earnings.

Sources: UHS Q1 2026 Earnings Call (April 28, 2026); UHS Q1 2026 10-Q; BofA Global Healthcare Conference (May 12, 2026); Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2026).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been modestly revised upward since the Q1 print — Q2 2026 operating EPS consensus moved from $5.77 to $5.96 (+3.3%) and FY2026 from $23.46 to $23.52 (+0.3%) — reflecting the Florida DPP disclosure and continued operational confidence, while behavioral volume estimates remain below management’s 2%–3% target, suggesting the Street is not yet fully pricing in the volume recovery thesis.

The upward revision in Q2 operating EPS (+3.3% since the Q1 print) is primarily attributable to the Florida FY2025 Medicaid supplemental payment disclosure (~$100M incremental benefit), which was not fully embedded in consensus at the time of the Q1 call. FY2026 estimates are essentially flat, suggesting the Street is treating the Florida DPP as a timing item rather than a structural upgrade. Behavioral volume estimates remain anchored at the low end of management’s 2%–3% target, representing a potential upside catalyst if Q2 execution shows acceleration.

Source: Visible Alpha Consensus and Actuals Data; UHS Q1 2026 Earnings Call (April 28, 2026); BofA Global Healthcare Conference (May 12, 2026); Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2026).

5. Stock Performance

Key Takeaway: UHS has dramatically underperformed since Q1 earnings — down ~4.2% vs. IHF +18.5% and SPY +3.8% — driven almost entirely by multiple compression and sentiment deterioration on Medicaid policy risk and exchange subsidy headwinds, not by estimate cuts; the stock’s compressed valuation (~7–8x EBITDA vs. 13–15x private market comps) creates an asymmetric setup if Q2 execution is clean.

UHS vs. IHF (iShares U.S. Healthcare Providers ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 28, 2026). Source: Yahoo Finance / Stock Price Data.

• UHS: -4.2% since Q1 earnings (Apr 28 – Jul 27, 2026); closed at $155.75 on July 27 vs. $162.54 on earnings day.
• IHF (iShares U.S. Healthcare Providers ETF): +18.5% over the same period — a massive divergence driven by HCA and THC outperformance on strong Q2 results and guidance raises.
• S&P 500 (SPY): +3.8% over the same period.
• Key driver of underperformance: Multiple compression on Medicaid policy risk (OB3 phasedown beginning 2028, exchange subsidy expiration), Laurel Ridge facility termination, and Talkspace acquisition overhang. Estimate revisions have been modestly positive, confirming the underperformance is sentiment/multiple-driven, not fundamental.
• Valuation context: Management noted UHS trades at ~7–8x EBITDA vs. 13–15x for private behavioral health transactions — a significant discount that management views as compelling and has backed with aggressive share repurchase (management guided to being “more aggressive” on buybacks in Q2 given the stock’s compelling value).
• Notable events marked: BofA Global Healthcare Conference (May 12), Goldman Sachs Healthcare Conference (June 9), and $700M delayed draw credit facility amendment (July 21).

Source: Stock Price Data (Yahoo Finance); UHS BofA Global Healthcare Conference (May 12, 2026); Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2026); UHS 8-K (July 21, 2026).

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the formal disclosure of the ~$100M incremental Florida FY2025 Medicaid supplemental payment to be recorded in Q2 — a material upside vs. the ~$50M initially guided — while the Laurel Ridge facility termination and Talkspace acquisition progress are the other key items to monitor.

• July 21, 2026 — $700M Delayed Draw Credit Facility Amendment (8-K): UHS boosted its credit facility with a $700M delayed draw term loan, providing additional liquidity ahead of the Talkspace acquisition close (expected Q3 2026). Implication: Signals Talkspace close is imminent; leverage expected to remain in low 2x range post-close, consistent with prior guidance.
• May 2026 — Florida FY2025 Medicaid Supplemental Payment Formally Approved: The Florida fiscal year 2025 DPP program (October 2024 – September 2025) was formally approved and disclosed in the Q1 2026 10-Q. The incremental benefit of ~$100M (vs. the prior program structure) will be recorded in Q2 2026 — materially above the ~$50M initially estimated on the Q1 call. Implication: Single largest Q2 earnings driver; already embedded in consensus but exact sizing could still surprise.
• May 2026 — Palm Beach Gardens (30th Hospital) Opened: UHS opened its 30th acute care hospital in Palm Beach Gardens, Florida (Jupiter area) in May 2026. Management described it as a “highly attractive market” but expects an operating loss for the year. Implication: Q2 will include the first full quarter of startup losses; partially offset by Cedar Hill improvement; management targets divisional-level performance by end of 2027.
• April 30, 2026 — Laurel Ridge Treatment Center Medicare/Medicaid Termination: UHS’s Laurel Ridge behavioral health facility in San Antonio, TX had its Medicare and Medicaid provider agreements terminated effective April 30, 2026 following CMS findings of noncompliance. Significant workforce reductions were announced. Implication: Management expects operating losses and cash flow deficits during the recertification period with no assurance of recertification; Q2 will be the first full quarter of impact; magnitude not explicitly quantified but likely a modest headwind.
• March 9, 2026 — Talkspace Acquisition Announced (On Track for Q3 2026 Close): UHS signed a definitive agreement to acquire Talkspace (~$800M) — a virtual behavioral health platform with 6,000 licensed professionals. Expected to close Q3 2026 (confirmed on track at GS conference). Implication: No Q2 P&L impact; post-close, adds ~300 bps to behavioral outpatient mix; slightly accretive in first 12 months; key strategic accelerant for the outpatient behavioral strategy.
• Q2 2026 — 178 New Acute Beds Across 3 Projects Online: Lakewood Ranch (West Coast Florida) tower, Henderson (Las Vegas) new floor, and Riverside County (California) replacement facility all came online during Q2, adding 178 incremental beds at existing hospitals. Implication: At existing hospitals, so expected to ramp faster than de novos; management expects “very positive impact on growth in the back half of the year.”
• Q2 2026 — California Nurse Staffing Ratio Requirements Effective June 1: California’s nurse staffing ratio requirements went into effect June 1, 2026. UHS had ~$5M readiness cost in Q1 and management stated it was “on track with assumptions contemplated in 2026 outlook.” Implication: Q2 will be the first quarter with full California staffing regulation impact; management has guided this is within their 2026 assumptions.
• June 9, 2026 — CMS Proposed Rule on State Directed Payments (SDP): CMS expanded SDP reform to cover nearly all Medicaid services including behavioral health, with total savings estimated north of $700B. Management reviewed the proposal and characterized it as containing “nothing materially new” relative to existing estimates. Implication: No change to UHS’s prior estimates of DPP benefits or the 2028 phasedown impact; administrative complexity around individual claim adjudication may draw comment but is not expected to change financial impact.
• Ongoing — AI Deployment Scaling: Management disclosed 8 distinct AI use cases in revenue cycle operations scaled in Q1 2026, contributing ~50 bps to revenue per adjusted admission in 2025. 2026 focus is shifting to clinical operations (Hippocratic AI partnership). Implication: Incremental margin tailwind; behavioral RCM AI improvement expected to be more of a 2027 driver given EHR implementation still in progress.

Sources: UHS 8-K (July 21, 2026); UHS Q1 2026 10-Q; UHS Q1 2026 Earnings Call (April 28, 2026); BofA Global Healthcare Conference (May 12, 2026); Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2026); UHS press releases.

7. Peer Commentaries — Q2 2026 Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from HCA (Q2 2026 results, July 24) and THC (Q2 2026 results, July 24) provides the most direct read-through for UHS’s Q2 print: both confirmed that exchange subsidy headwinds steepened materially in Q2 (HCA: -$400M EBITDA impact; THC: exchange revenues -17%), but both also reported strong underlying demand and raised full-year guidance on fundamental outperformance — a constructive read-through for UHS’s acute segment, while ACHC’s behavioral volume acceleration (+6.5% same-store admissions) is a positive signal for UHS’s behavioral segment.

Note: Only commentary from the current reporting period (Q2 2026) is included below. Q1 2026 earnings calls from peers (which reported on Q1 results) are included only where they provided explicit forward commentary about Q2 2026 trends.

HCA Healthcare (HCA) — Q2 2026 Earnings (July 24, 2026)

Read-Through Relevance: HCA is the largest U.S. acute care hospital operator and the most direct read-through for UHS’s acute segment. HCA’s Q2 2026 results are the most timely and relevant peer data point available.

• Exchange headwinds steepened sharply in Q2 — negative for UHS acute: HCA reported exchange revenues declined 17% YoY in Q2 and exchange volume admissions were down ~13.5%. The exchange subsidy expiration had an unfavorable EBITDA impact of ~$400M in Q2 (including a ~$75M revision to Q1 estimates). HCA noted a near 1-for-1 migration of exchange patients to uninsured. UHS read-through: UHS guided to a $75M full-year exchange headwind with steepening through the year; Q2 will likely show the largest single-quarter impact. HCA’s experience validates UHS’s payer mix shift assumption (exchange → uninsured, not volume loss).
• Florida Medicaid supplemental payment was a major Q2 driver — positive for UHS: HCA recognized a $540M incremental net benefit from the Florida program (covering October 2024 – June 2026, 21 months of benefit) in Q2. Total incremental Medicaid supplemental benefit in Q2 was ~$400M. UHS read-through: UHS’s Florida FY2025 program (October 2024 – September 2025) was approved at ~$100M incremental benefit — consistent with the BofA conference disclosure. HCA’s experience confirms the Florida program was recorded in Q2 as expected.
• Underlying demand remains healthy despite payer mix pressure — positive for UHS: HCA reported same-facility admissions +2.5% and equivalent admissions +2.7% in Q2, with ER visits +3.6%. Insured volumes (ex-exchange) showed solid growth. Medicare equivalent admissions +3.6%, Medicaid +2.7%, commercial (ex-exchange) +3.2%. UHS read-through: Healthy underlying demand environment supports UHS’s acute volume recovery thesis; new capacity additions (178 beds in Q2) should benefit from this demand backdrop.
• Elective surgery softness is a watch item — modest negative for UHS: HCA reported inpatient surgeries -2.3% and outpatient surgeries -3.4%, with elective inpatient surgeries down 6% (vs. -2% in 2025). Physicians cited general affordability and economic pressures. UHS read-through: UHS’s acute segment has less surgical mix than HCA, but elective softness could weigh on acute revenue per admission if acuity mix shifts.
• Full-year guidance revised to reflect exchange headwinds — mixed for UHS: HCA revised FY2026 guidance: revenue $77B–$79.5B, adjusted EBITDA $15.4B–$16.1B, diluted EPS $28.70–$30.50. Key assumptions: exchange EBITDA impact -$1.0B to -$1.2B (full year); Medicaid supplemental net benefit $300M–$500M (H2 headwind as 2025 approvals/retro payments exceed incremental Florida benefit). UHS read-through: HCA’s H2 Medicaid supplemental headwind (2025 approvals exceeding incremental Florida benefit) is a relevant framework for UHS — UHS’s H2 will also face tougher comps on supplemental payments.

Source: HCA Healthcare Q2 2026 Earnings Call (July 24, 2026).

Tenet Healthcare (THC) — Q2 2026 Earnings (July 24, 2026)

Read-Through Relevance: THC is a major acute care hospital operator with significant overlap in UHS’s key markets (Florida, Texas, California). THC’s Q2 2026 results provide a direct read-through for acute hospital operating trends.

• Strong Q2 beat and guidance raise — positive read-through for UHS: THC reported Q2 2026 consolidated adjusted EBITDA of $1.304B (+16.3% YoY), adjusted diluted EPS of $6.12 (+52% YoY), and raised FY2026 adjusted EBITDA guidance by $295M (6%) at the midpoint to $4.83B–$5.03B. The raise was supported by ~$100M of fundamental outperformance in H1 plus $60M expected from continuation of those drivers in H2. UHS read-through: THC’s strong fundamental outperformance (ex-supplemental payments) is a positive signal for the acute hospital operating environment heading into UHS’s Q2 print.
• Exchange headwinds confirmed and quantified — validates UHS’s assumptions: THC reported exchange revenues -17% YoY in Q2, exchange volume admissions -13.5%, and a ~$65M revenue headwind from exchange declines in Q2. THC expects Q2 market trends to “roughly continue into Q3 and Q4.” Near 1-for-1 conversion of exchange patients to uninsured confirmed. UHS read-through: Consistent with UHS’s $75M full-year exchange headwind assumption; Q2 steepening is in line with management’s guidance.
• Florida Medicaid supplemental payment confirmed as Q2 driver: THC cited the Florida program as a contributor to the Medicaid delta in Q2, with $92M of favorable out-of-period supplemental Medicaid revenues recognized in Q2 (vs. $70M in Q2 2025). FY2026 supplemental contribution now expected at $140M. UHS read-through: Confirms Florida DPP was recorded in Q2 as expected; UHS’s ~$100M incremental benefit is consistent with the peer experience.
• Hospital segment EBITDA margin expansion — positive for UHS: THC’s hospital segment adjusted EBITDA was $762M (+22% YoY) with an 18% EBITDA margin. Revenue per adjusted admission +3.3% YoY. Technology-enabled expense management (AI, global business center) cited as a key driver. UHS read-through: Margin expansion at peers despite exchange headwinds is a positive signal; UHS’s AI-driven revenue cycle improvements (~50 bps to revenue per adjusted admission in 2025) are a similar tailwind.
• Same-hospital inpatient adjusted admissions +2.6% — positive for UHS volume outlook: THC reported same-hospital inpatient adjusted admissions +2.6% in Q2, a sequential improvement from Q1, “further validation that the demand environment remains healthy.” UHS read-through: Supports UHS’s expectation of improving acute volume trends in Q2 as new capacity ramps and seasonal factors normalize.

Source: Tenet Healthcare Q2 2026 Earnings Call (July 24, 2026).

Acadia Healthcare (ACHC) — Q1 2026 Earnings (April 30, 2026) — Forward Commentary on Q2 2026

Read-Through Relevance: ACHC is the most direct behavioral health peer to UHS. ACHC’s Q1 2026 results and Q2 2026 guidance provide the most relevant read-through for UHS’s behavioral segment.

• Behavioral demand remains strong and accelerating — positive for UHS behavioral: ACHC reported same-store admissions +6.5% in Q1 2026, with acute inpatient psychiatric revenue +14% YoY and inpatient volumes +6.2%. Inquiries for acute care were up over 20% in Q1. Management stated demand is “continuing to be strong” and has “actually strengthened.” UHS read-through: ACHC’s strong behavioral volume acceleration is a positive signal for the demand environment; UHS’s lower volume growth (1.6% in Q1) reflects staffing constraints and mix, not demand weakness.
• Labor cost moderation continuing — positive for UHS behavioral margins: ACHC reported same-facility labor costs +3.7% YoY but only +2.0% on a per patient day basis (same as Q4 2025). Staff retention improved for the 8th consecutive quarter. Premium labor spend declined 9.4% YoY. UHS read-through: Consistent with UHS’s expectation of moderating behavioral labor cost growth in 2026 (headcount growth stepping down to ~2% from 4% in 2025); supports the margin improvement thesis.
• Bad debts and denials running hotter than expected — watch item for UHS: ACHC noted “modestly higher-than-expected levels of bad debts and denials” that continued to worsen in Q1 beyond expectations, described as “broad-based across payer types.” ACHC brought in a consultant to evaluate and improve the area. UHS read-through: UHS has been investing in AI-driven denial management (generating tens of millions in annual uplift); ACHC’s experience highlights that denial management remains an industry-wide challenge and UHS’s AI advantage may be a relative differentiator.
• Q2 2026 guidance provided — direct read-through: ACHC guided Q2 2026 revenue of $835M–$850M, adjusted EBITDA of $142M–$152M, and adjusted EPS of $0.30–$0.40. Start-up losses expected at $15M in Q2 (high end for the year). Two new facilities expected to open in Q2. UHS read-through: ACHC’s Q2 guidance implies continued growth but with startup losses as a headwind — consistent with UHS’s own de novo ramp dynamics (Palm Beach Gardens, behavioral de novos).
• Commercial payer mix improving — positive for behavioral margins: ACHC noted its commercial payer mix is up, having “strengthened” its focus on commercial patients after a period of de-emphasis. UHS read-through: Consistent with UHS’s outpatient behavioral expansion strategy (Talkspace, Thousand Branches) which targets a more commercially-insured mix; outpatient behavioral margins are better than inpatient due to commercial/Medicare payer mix.

Source: Acadia Healthcare Q1 2026 Earnings Call (April 30, 2026).

Encompass Health (EHC) — Q1 2026 Earnings (May 1, 2026) — Forward Commentary on Q2 2026

Read-Through Relevance: EHC is an inpatient rehabilitation facility (IRF) operator — a different sub-sector from UHS’s acute/behavioral model, but relevant for read-throughs on Medicare Advantage dynamics, labor trends, and overall healthcare demand.

• IRF demand remains strong with volume growth accelerating — broadly positive for healthcare demand: EHC reported Q1 2026 revenue +9% YoY, adjusted EBITDA +11.2%, and discharge growth of 4.3% (including 1.6% same-store). Management raised FY2026 guidance to net revenue $6.375B–$6.470B and adjusted EBITDA $1.35B–$1.38B. Volume growth expected to accelerate through the balance of 2026 as bed additions come online (70% of 2026 bed additions in H2). UHS read-through: Healthy IRF demand environment is consistent with UHS’s acute demand thesis; EHC’s back-half volume acceleration from new capacity mirrors UHS’s own H2 ramp expectations.
• Medicare Advantage penetration peaking and receding — positive for acute/behavioral payer mix: EHC noted MA penetration appears to have peaked at ~52% of Medicare beneficiaries and is now receding slightly, with 20 states experiencing a decline in MA penetration in the 12 months ending March 2026. EHC implemented an “admit-and-appeal” strategy for denied MA patients with early success (~30% overturn rate at first appeal level). UHS read-through: MA penetration peaking is a broadly positive signal for hospital operators; less MA pressure means more fee-for-service Medicare volume, which is generally better-reimbursed.
• Labor cost improvement continuing — positive for UHS: EHC reported premium labor spend -9.4% YoY in Q1, contract labor FTEs at 1.2% of total (down 10 bps YoY), and annualized RN turnover at 17.8% (lowest since at least 2012, down from 20.2% in FY2025). UHS read-through: Broad-based labor market improvement across healthcare sub-sectors is consistent with UHS’s expectation of moderating behavioral labor cost growth in 2026.
• Medicaid directed payment revenue larger than anticipated in Q1 — positive for UHS supplemental payment thesis: EHC noted Q1 Medicaid directed payment revenue was “larger than anticipated, largely due to a significant portion being out of period,” with an EBITDA impact from the out-of-period portion of ~$4.2M. Full-year net provider tax EBITDA impact still expected at ~$21M (flat YoY). UHS read-through: Confirms that Medicaid supplemental payment timing surprises (both positive and negative) are common across the sector; UHS’s Florida DPP recording in Q2 is consistent with the broader pattern.

Source: Encompass Health Q1 2026 Earnings Call (May 1, 2026); Encompass Health BofA Global Healthcare Conference (May 12, 2026).

Tenet Healthcare (THC) — Q1 2026 Earnings (April 30, 2026) — Forward Commentary on Q2 2026

Read-Through Relevance: THC’s Q1 2026 earnings call provided explicit Q2 2026 guidance and forward commentary on exchange subsidy trends, Medicaid supplemental payments, and demand — all directly relevant to UHS’s Q2 setup.

• Exchange headwinds expected to steepen in Q2 — validates UHS’s guidance: THC reported Q1 exchange admissions -10% YoY (better than the full-year -20% assumption). Management explicitly stated the impact would “get worse over the course of the year due to grace period dynamics and effectuation dynamics.” Q2 consolidated adjusted EBITDA guided at 24%–25% of full-year midpoint. UHS read-through: Confirms UHS’s Q2 exchange headwind will be larger than Q1’s $15M; the steepening is expected and in guidance.
• Fundamental demand improving through Q1 — positive for UHS: THC noted that “every month got better” through Q1, with March above expectations. Physician practices described as “busy.” Management stated they were “more bullish” about guidance trajectory than at the start of the year. UHS read-through: Improving demand trajectory through Q1 supports UHS’s expectation of better Q2 acute volumes as seasonal headwinds (flu, weather) dissipate.
• Expense management and AI driving margin improvement — positive for UHS: THC highlighted technology and AI-driven expense reduction plans being executed, with SWB at 40.5% of net revenues (consistent with prior year despite revenue headwinds). Management cited “traditional and innovative levers with technology, AI and other things” building over time. UHS read-through: Consistent with UHS’s AI-driven revenue cycle and clinical efficiency initiatives; sector-wide technology adoption is a margin tailwind.

Source: Tenet Healthcare Q1 2026 Earnings Call (April 30, 2026); Tenet Healthcare BofA Global Healthcare Conference (May 13, 2026).

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells were filed in the period since Q1 earnings — the only Form 4 activity consists of routine director equity award grants (transaction code ‘A’) and a large non-cash transfer by Executive Chairman Alan Miller (transaction code ‘J’, a gift or estate planning transfer, not a market sale). There is no insider signal — positive or negative — from the Form 4 data.

No open-market buys (Form 4 code P) or open-market sells (Form 4 code S) were filed by UHS insiders in the period since Q1 2026 earnings (April 28, 2026 through July 26, 2026). The absence of discretionary insider selling is a mild positive signal given the stock’s ~4% decline since earnings, though the absence of open-market buying is notable given management’s public statements about the stock’s “compelling value.” The company’s capital return activity has been expressed through corporate share repurchases rather than individual insider purchases.

Source: SEC Form 4 filings (Insider Transaction Data).